THE TRIAL RECORD
The semaglutide research base: mechanism first, then the trials that built every approval.
From the brain circuits that drive the weight effect to the outcome trials that moved it past the scale — each finding pinned to its source.
Start here
This page walks the semaglutide research record in order: first what the molecule is, then how it works, then the big trials grouped by what they measured — weight, blood sugar, heart, kidney, liver — and finally how it stacks up against tirzepatide. If you only read one thing: semaglutide is an FDA-approved copy of a natural gut hormone (GLP-1) that, in a large trial, lowered body weight by about 15% over 68 weeks [1], cut heart-attack-and-stroke risk by 20% in people with heart disease [3], and slowed kidney decline in diabetes by 24% [6]. The depth, with every number cited and the jargon glossed as it appears, is below.
What is semaglutide
What is semaglutide? It is a 31-amino-acid acylated analogue of human GLP-1 (glucagon-like peptide-1) — about 94% the same as the natural hormone, with three deliberate changes [11]. Two backbone substitutions block the enzyme DPP-4 (dipeptidyl peptidase-4, which normally chews up GLP-1 in minutes), and a C18 fatty-acid side chain makes the molecule cling to albumin, the most abundant protein in blood. That albumin grip slows clearance and is the reason a once-weekly shot is possible at all [11]. Its molecular formula is C187H291N45O59. It belongs to the GLP-1 receptor agonist (incretin mimetic) drug class — the same family as liraglutide and dulaglutide.
How does semaglutide work
How does semaglutide work? On two fronts. In the pancreas and gut, it does the classic incretin jobs: it potentiates glucose-dependent insulin secretion (insulin released only when blood sugar is high, so the risk of lows is small), suppresses inappropriate glucagon (the hormone that raises blood sugar), and slows gastric emptying [5]. That delayed emptying contributes to fullness — and to the early nausea.
The weight effect, though, is mostly central. Rodent work showed semaglutide directly accessing the brainstem, area postrema, hypothalamic arcuate nucleus and parabrachial nucleus — the appetite-control hubs — where it activates the satiety-signaling POMC/CART neurons and inhibits the hunger-driving NPY/AgRP neurons, reducing food intake and shifting food preference without lowering energy expenditure [4]. In plain terms: it turns the brain's hunger dial down rather than speeding up calorie burn.
Semaglutide peptide: the weight-management trials
As a peptide medicine, the semaglutide peptide's weight evidence is anchored by STEP 1: once-weekly subcutaneous 2.4 mg produced a mean body-weight change of -14.9% from baseline to week 68 versus -2.4% with placebo (a treatment difference near 12.4 percentage points) in adults with overweight or obesity without diabetes [1]. The durability question is answered by the STEP 4 design and the STEP 1 extension, which together show continued loss on drug and substantial regain off it — a mean of about 11.6 percentage points regained within a year of stopping [17]. A 2025 narrative review frames the program as a major advance in obesity treatment [10]. The dedicated semaglutide weight loss page goes deeper on these numbers.
Glycemic control in type 2 diabetes
In type 2 diabetes, the SUSTAIN (subcutaneous) and PIONEER (oral) programs established HbA1c lowering across the dose range. SUSTAIN FORTE showed once-weekly 2.0 mg gave greater HbA1c reduction than 1.0 mg, supporting the higher approved diabetes dose [9]. HbA1c — glycated hemoglobin — is a blood marker reflecting average glucose over about three months, and it is the primary efficacy measure in these trials. The mechanism is the glucose-dependent insulin and glucagon effects described above [5].
Cardiovascular outcomes
This is where semaglutide moved past glucose and weight. In SUSTAIN-6 (n=3,297), in type 2 diabetes at high cardiovascular risk, it reduced the composite of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke (HR 0.74; 95% CI 0.58-0.95) — though it also showed more diabetic-retinopathy complications (HR 1.76; 95% CI 1.11-2.78) [2]. Then SELECT (n=17,604) extended the benefit to people with established cardiovascular disease and obesity but no diabetes: a 20% reduction in major adverse cardiovascular events (MACE) versus placebo (HR 0.80; 95% CI 0.72-0.90; P<0.001) [3]. MACE — major adverse cardiovascular events — is the composite endpoint these trials are built around.
Kidney and liver outcomes
The protection kept widening. In FLOW (n=3,533), in type 2 diabetes with chronic kidney disease, once-weekly 1.0 mg reduced major kidney-disease events — kidney failure, a 50% or greater drop in kidney function, or kidney/cardiovascular death — by 24% versus placebo (HR 0.76; 95% CI 0.66-0.88) [6]. In the liver, the ESSENCE phase-3 trial in biopsy-confirmed MASH (metabolic dysfunction-associated steatohepatitis, a progressive fatty-liver disease) achieved resolution of steatohepatitis without worsening fibrosis in 62.9% on semaglutide versus 34.3% on placebo, and fibrosis improvement in 36.8% versus 22.4% [12]. That trial underpins the 2025 MASH indication.
Pharmacokinetics and half-life
Semaglutide's elimination half-life is approximately one week (commonly cited as ~165-168 hours) for both the subcutaneous and oral forms, with effectively complete clearance about five weeks after the last dose [11]. That long half-life — from the albumin binding plus DPP-4 resistance described earlier — is the structural basis for once-weekly dosing and for the multi-week washout advised before pregnancy. A systematic review summarizes the broader PK picture across formulations [10].
How it compares with tirzepatide
The cleanest comparison is the SURMOUNT-5 head-to-head (n=751) in adults with obesity: tirzepatide produced greater mean weight loss than semaglutide at 72 weeks (-20.2% vs -13.7%; P<0.001) [7]. SURPASS-2 showed tirzepatide superior on HbA1c and weight in type 2 diabetes [8], and a 2025 modelling study compared their projected 10-year cardiovascular-risk impact [22]. Tirzepatide is a dual GIP/GLP-1 agonist — it hits a second gut-hormone receptor (GIP) on top of GLP-1 — which is the leading explanation for the gap. The full side-by-side is on the semaglutide vs tirzepatide page.